Possibilities Of Prevention And Treatment Of Human Cytomegalovirus Infections Including New Drugs And Compounds With Potential Application

1.Biron K.K.: Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71, 154–163 (2006)BironK.K.Antiviral drugs for cytomegalovirus diseasesAntiviral Res.71154163200610.1016/j.antiviral.2006.05.00216765457Search in Google Scholar

2.Bocian J., Januszkiewicz-Lewandowska D.: HCMV infections after hematopoietic stem cell transplantation – diagnostic methods and importance of viral DNA level monitoring. Post. Hig. Med. Dosw. 69, 252–263 (2015)BocianJ.Januszkiewicz-LewandowskaD.HCMV infections after hematopoietic stem cell transplantation – diagnostic methods and importance of viral DNA level monitoringPost. Hig. Med. Dosw.69252263201510.5604/17322693.114110025720612Search in Google Scholar

3.Bright P.D., Gompels M., Donati M., Johnston S.: Successful oral treatment of ganciclovir resistant cytomegalovirus with maribavir in the context of primary immunodeficiency: First case report and review. J. Clin. Virol. 87, 12–16 (2017)BrightP.D.GompelsM.DonatiM.JohnstonS.Successful oral treatment of ganciclovir resistant cytomegalovirus with maribavir in the context of primary immunodeficiency: First case report and reviewJ. Clin. Virol.871216201710.1016/j.jcv.2016.12.00627987421Search in Google Scholar

4.Britt W.J., Prichard M.N.: New therapies for human cytomegalovirus infections. Antiviral Res. 159, 153–174 (2018)BrittW.J.PrichardM.N.New therapies for human cytomegalovirus infectionsAntiviral Res.159153174201810.1016/j.antiviral.2018.09.00330227153Search in Google Scholar

5.Chaer F.E., Shah D.P., Chemaly R.F.: How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood 128, 2624–2636 (2016)ChaerF.E.ShahD.P.ChemalyR.F.How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsBlood12826242636201610.1182/blood-2016-06-688432514674427760756Search in Google Scholar

6.Chemaly RF, Hill J., Voigt S., Peggsd K.S.: In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review. Antiviral Res. 163, 50–58 (2019)ChemalyRFHillJ.VoigtS.PeggsdK.S.In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature reviewAntiviral Res.1635058201910.1016/j.antiviral.2019.01.00830677427Search in Google Scholar

7.Chen H., Li C., Zemlicka J., Gentry B.G., Bowlin T.L., Coena D.M.: Potency and stereoselectivity of cyclopropavir triphosphate action on human cytomegalovirus DNA Polymerase. Antimicrob. Agents Chemother. 60, 4176–4182 (2016)ChenH.LiC.ZemlickaJ.GentryB.G.BowlinT.L.CoenaD.M.Potency and stereoselectivity of cyclopropavir triphosphate action on human cytomegalovirus DNA PolymeraseAntimicrob. Agents Chemother.6041764182201610.1128/AAC.00449-16491463127139481Search in Google Scholar

8.Chou S.: Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. Antiviral Res. 138, 57–60 (2017)ChouS.Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase geneAntiviral Res.1385760201710.1016/j.antiviral.2016.12.003520925027940027Search in Google Scholar

9.Chou S., Ercolani R.J., Derakhchan. K.: Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. Antiviral Res. 157, 128–133 (2018)ChouS.ErcolaniR.J.DerakhchanK.Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirusAntiviral Res.157128133201810.1016/j.antiviral.2018.07.013609780630040968Search in Google Scholar

10.Czarnecka P., Czarnecka K., Tronina O., Durlik M.: Cytomegalovirus disease after liver transplant-a description of a treatment-resistant case: a case report and literature review. Transplant Proc. 50, 4015–4020 (2018)CzarneckaP.CzarneckaK.TroninaO.DurlikM.Cytomegalovirus disease after liver transplant-a description of a treatment-resistant case: a case report and literature reviewTransplant Proc.5040154020201810.1016/j.transproceed.2018.05.01430577306Search in Google Scholar

11.Dadwal S.S.: Update on prevention of cytomegalovirus in hematopoietic cell transplantation. Curr. Opin. Infect. Dis. 32, 63–68 (2019)DadwalS.S.Update on prevention of cytomegalovirus in hematopoietic cell transplantationCurr. Opin. Infect. Dis.326368201910.1097/QCO.000000000000051730543548Search in Google Scholar

12.Dęborska-Materkowska D., Durlik M.: Leczenie zakażenia wirusem cytomegalii po transplantacji nerki. Forum Nefrologiczne 3, 162–168 (2010)Dęborska-MaterkowskaD.DurlikM.Leczenie zakażenia wirusem cytomegalii po transplantacji nerkiForum Nefrologiczne31621682010Search in Google Scholar

13.Durlik M.: Cytomegalovirus infection in transplant recipients. Nefrol. Dial. Pol. 13, 157–163 (2009)DurlikM.Cytomegalovirus infection in transplant recipientsNefrol. Dial. Pol.131571632009Search in Google Scholar

14.Dzieciątkowski T., Rola A., Majewska A., Solarska M., Łuczak M.: Leki stosowane w leczeniu zakażeń herpeswirusami u ludzi. Post. Mikrobiol. 46, 211–221 (2007)DzieciątkowskiT.RolaA.MajewskaA.SolarskaM.ŁuczakM.Leki stosowane w leczeniu zakażeń herpeswirusami u ludziPost. Mikrobiol.462112212007Search in Google Scholar

15.Foster S.A., Parker S., Lanier R.: The role of brincidofovir in preparation for a potential smallpox outbreak. Viruses 9, 320 (2017)FosterS.A.ParkerS.LanierR.The role of brincidofovir in preparation for a potential smallpox outbreakViruses9320201710.3390/v9110320570752729773767Search in Google Scholar

16.Frange P., Leruez-Ville M.: Maribavir, brincidofovir and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infections. Med. Mal. Infect. 48, 495–502 (2018)FrangeP.Leruez-VilleM.Maribavir, brincidofovir and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infectionsMed. Mal. Infect.48495502201810.1016/j.medmal.2018.03.00629650261Search in Google Scholar

17.Gentry B.G., Drach J.C.: Metabolism of cyclopropavir and ganciclovir in Human Cytomegalovirus-infected cells. Antimicrob. Agents Chemother. 58, 2329–2333 (2014)GentryB.G.DrachJ.C.Metabolism of cyclopropavir and ganciclovir in Human Cytomegalovirus-infected cellsAntimicrob. Agents Chemother.5823292333201410.1128/AAC.02311-13402380224514084Search in Google Scholar

18.Jackson J.W., Hancock T.J., Dogra P., Patel R., Arav-Boger R., Williams A.D., Kennel S.J., Wall J.S., Sparer T.E.: Anticytomegalovirus peptides point to new insights for CMV entry mechanisms and the limitations of in vitro screenings. mSphere, 13, e00586–18 (2019)JacksonJ.W.HancockT.J.DograP.PatelR.Arav-BogerR.WilliamsA.D.KennelS.J.WallJ.S.SparerT.E.Anticytomegalovirus peptides point to new insights for CMV entry mechanisms and the limitations of in vitro screeningsmSphere13e0058618201910.1128/mSphere.00586-18637459330760613Search in Google Scholar

19.Koval C.E.: Prevention and treatment of cytomegalovirus infections in solid organ transplant recipients. Infect. Dis. Clin. North Am. 32, 581–559 (2018)KovalC.E.Prevention and treatment of cytomegalovirus infections in solid organ transplant recipientsInfect. Dis. Clin. North Am.32581559201810.1016/j.idc.2018.04.00830146024Search in Google Scholar

20.Leś, nikowski Z.J., Paradowska E., Przepiórkiewicz M., Bogusława-Olejniczak A., Emery V.: Leki przeciwko ludzkiemu wirusowi cytomegalii (hCMV). Pol. Merkur. Lek. XIII, 242–249 (2002)LeśnikowskiZ.J.ParadowskaE.PrzepiórkiewiczM.Bogusława-OlejniczakA.EmeryV.Leki przeciwko ludzkiemu wirusowi cytomegalii (hCMV)Pol. Merkur. Lek.XIII2422492002Search in Google Scholar

21.Ligat G., Cazal R., Hantz S., Alain S.: The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol. Rev. 42, 137–145 (2018)LigatG.CazalR.HantzS.AlainS.The human cytomegalovirus terminase complex as an antiviral target: a close-up viewFEMS Microbiol. Rev.42137145201810.1093/femsre/fuy004597266029361041Search in Google Scholar

22.Majewska A., Młynarczyk-Bonikowska B., Malejczyk M., Majewski S., Młynarczyk G.: Antiviral medication in sexually transmitted diseases. Part III: Hepatitis B, Hepatitis C. Mini Rev. Med. Chem. 17, 328–337 (2017)MajewskaA.Młynarczyk-BonikowskaB.MalejczykM.MajewskiS.MłynarczykG.Antiviral medication in sexually transmitted diseases. Part III: Hepatitis B, Hepatitis CMini Rev. Med. Chem.17328337201710.2174/138955751666616080811440827515715Search in Google Scholar

23.Majewska A., Młynarczyk-Bonikowska B., Malejczyk M., Młynarczyk G., Majewski S.: Antiviral medication in sexually transmitted diseases. Part II: HIV. Mini Rev. Med. Chem. 15, 93–103 (2015)MajewskaA.Młynarczyk-BonikowskaB.MalejczykM.MłynarczykG.MajewskiS.Antiviral medication in sexually transmitted diseases. Part II: HIVMini Rev. Med. Chem.1593103201510.2174/13895575150215030515445925751258Search in Google Scholar

24.Marty F.M., Badshah C. i wsp.: Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N. Engl. J. Med. 377, 2433–2444 (2017)MartyF.M.BadshahC.i wspLetermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantationN. Engl. J. Med.37724332444201710.1056/NEJMoa170664029211658Search in Google Scholar

25.McIntosh M., Hauschild B., Miller V.: Human cytomegalovirus and transplantation: drug development and regulatory issues. J. Virus Erad. 2, 143–148 (2016)McIntoshM.HauschildB.MillerV.Human cytomegalovirus and transplantation: drug development and regulatory issuesJ. Virus Erad.2143148201610.1016/S2055-6640(20)30457-XSearch in Google Scholar

26.Mizuguchi T., Ohashi N., Matsumoto D., Hashimoto C., Nomura W., Yamamoto N., Murakami T., Tamamura H.: Development of anti-HIV peptides based on a viral capsid protein. Biopolymers, 108, DOI: 10.1002/bip.22920 (2017)MizuguchiT.OhashiN.MatsumotoD.HashimotoC.NomuraW.YamamotoN.MurakamiT.TamamuraH.Development of anti-HIV peptides based on a viral capsid proteinBiopolymers108DOI:10.1002/bip.22920201727428649Open DOISearch in Google Scholar

27.Młynarczyk-Bonikowska B, Majewska A., Malejczyk M., Młynarczyk G., Majewski S.: Antiviral medication in sexually transmitted diseases. Part I: HSV, HPV. Mini Rev. Med. Chem. 3, 1837–1845 (2013)Młynarczyk-BonikowskaBMajewskaA.MalejczykM.MłynarczykG.MajewskiS.Antiviral medication in sexually transmitted diseases. Part I: HSV, HPVMini Rev. Med. Chem.318371845201310.2174/1389557511313666008824032509Search in Google Scholar

28.Ndeboko B., Hantz O., Lemamy G.J., Cova L.: Developments in cell-penetrating peptides as antiviral agents and as vehicles for delivery of peptide nucleic acid targeting hepadnaviral replication pathway. Biomolecules, 8, DOI: 10.3390/biom8030055 (2018)NdebokoB.HantzO.LemamyG.J.CovaL.Developments in cell-penetrating peptides as antiviral agents and as vehicles for delivery of peptide nucleic acid targeting hepadnaviral replication pathwayBiomolecules8DOI:10.3390/biom80300552018616505830013006Open DOISearch in Google Scholar

29.O’, Brien M.S., Markovich K.C., Selleseth D., DeVita A.V., Sethna P., Gentry B.G.: In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus. Antiviral Res. 158, 255–263 (2018)O’, BrienM.S.MarkovichK.C.SellesethD.DeVitaA.V.SethnaP.GentryB.G.In vitro evaluation of current and novel antivirals in combination against human cytomegalovirusAntiviral Res.158255263201810.1016/j.antiviral.2018.08.01530153445Search in Google Scholar

30.Piret J., Boivin G.: Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. Antiviral Res. 163, 91–105 (2019)PiretJ.BoivinG.Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistanceAntiviral Res.16391105201910.1016/j.antiviral.2019.01.01130690043Search in Google Scholar

31.Pokorska-Śpiewak M., Niezgoda A., Gołkowska M., Czech-Kowalska J., Gruszfeld D., Dobrzańska A., Styczyński J., Marczyńska M.: Recommendations for the diagnosis and treatment of CMV infections. Polish Society of Epidemiology and Infectious Diseases. Przegl. Epidemiol. 70, 297–310 (2016)Pokorska-ŚpiewakM.NiezgodaA.GołkowskaM.Czech-KowalskaJ.GruszfeldD.DobrzańskaA.StyczyńskiJ.MarczyńskaM.Recommendations for the diagnosis and treatment of CMV infections. Polish Society of Epidemiology and Infectious DiseasesPrzegl. Epidemiol.702973102016Search in Google Scholar

32.Poole C.L., James S.H.: Antiviral therapies for Herpesviruses: current agents and new directions. Clin. Ther. 40, 1282–1298 (2018)PooleC.L.JamesS.H.Antiviral therapies for Herpesviruses: current agents and new directionsClin. Ther.4012821298201810.1016/j.clinthera.2018.07.006772815830104016Search in Google Scholar

33.Razonable R.R.: Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin. Proc. 86, 1009–1026 (2011)RazonableR.R.Antiviral drugs for viruses other than human immunodeficiency virusMayo Clin. Proc.8610091026201110.4065/mcp.2011.0309318403221964179Search in Google Scholar

34.Razonable R.R.: Drug-resistant cytomegalovirus: clinical implications of specific mutations. Curr. Opin. Organ Transplant. 23, 388–394 (2018)RazonableR.R.Drug-resistant cytomegalovirus: clinical implications of specific mutationsCurr. Opin. Organ Transplant.23388394201810.1097/MOT.000000000000054129794552Search in Google Scholar

35.Styczynski J.: Who is the patient at risk of CMV recurrence: A review of the current scientific evidence with a focus on hematopoietic cell transplantation. Infect. Dis. Ther. 7, 1–16 (2017)StyczynskiJ.Who is the patient at risk of CMV recurrence: A review of the current scientific evidence with a focus on hematopoietic cell transplantationInfect. Dis. Ther.7116201710.1007/s40121-017-0180-z584009929204910Search in Google Scholar

36.Tan B.H.: Cytomegalovirus treatment. Curr Treat Options Infect Dis. 6, 256–270 (2014)TanB.H.Cytomegalovirus treatmentCurr Treat Options Infect Dis.6256270201410.1007/s40506-014-0021-5443171325999800Search in Google Scholar

37.Tippin T.K., Morrison M.E., Brundage T.M., Momméja-Marin H. : Brincidofovir is not a substrate for the human organic anion transporter 1: A mechanistic explanation for the lack of nephrotoxicity observed in clinical studies. Ther. Drug. Monit. 38, 777–786 (2016)TippinT.K.MorrisonM.E.BrundageT.M.Momméja-MarinH.Brincidofovir is not a substrate for the human organic anion transporter 1: A mechanistic explanation for the lack of nephrotoxicity observed in clinical studiesTher. Drug. Monit.38777786201610.1097/FTD.0000000000000353511323827851688Search in Google Scholar

38.Tylden G.D., Hirsch H.H., Rinaldo C.H.: Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells. Antimicrob. Agents Chemother. 59, 3306–3316 (2015)TyldenG.D.HirschH.H.RinaldoC.H.Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cellsAntimicrob. Agents Chemother.5933063316201510.1128/AAC.00238-15443211925801568Search in Google Scholar

39.Wong D.D., van , Zuylen W.J., Craig M.E., Rawlinson W.D.: Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients. Rev. Med. Virol. 29, e2023, DOI: 10.1002/rmv.2023 (2019)WongD.D., van , ZuylenW.J.CraigM.E.RawlinsonW.D.Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipientsRev. Med. Virol.29e2023DOI:10.1002/rmv.2023201930556615Open DOISearch in Google Scholar

40.Wu Z., Drach J.C., Prichard M.N., Yanachkova M., Yanachkov I., Bowlin T.L., Zemlicka J.: L-valine ester of cyclopropavir: a new antiviral prodrug. Antivir. Chem. Chemother. 20, 37–46 (2009)WuZ.DrachJ.C.PrichardM.N.YanachkovaM.YanachkovI.BowlinT.L.ZemlickaJ.L-valine ester of cyclopropavir: a new antiviral prodrugAntivir. Chem. Chemother.203746200910.3851/IMP782293127219794230Search in Google Scholar

41.Zhao H., Zheng B.J. i wsp.: A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci. Rep. 6, DOI: 10.1038/srep22008 (2016)ZhaoH.ZhengB.J.i wspA novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory virusesSci. Rep.6DOI:10.1038/srep220082016476650326911565Open DOISearch in Google Scholar